Avenue Supermarkets in focus on QIP

Image
Capital Market
Last Updated : Feb 11 2020 | 6:31 PM IST

Avenue Supermarts, the company, which owns and operates popular supermarket chain DMart, launched a qualified institutional placement (QIP) offering to raise up to Rs 4,000 crore at Rs 1,999.04 per share. Funds will be used to expand the company's store network, invest in supply chain and also to repay loans.

ITI said the company has withdrawn FPO due to prevailing market condition.

Hindustan Aeronautics (HAL) said the company, Israel Aerospace Industries (IAI) and Dynamatic Technologies (DTL) signed a memorandum of understanding (MoU) for marketing, manufacturing and selling of IAI's Unmanned Ariel Vehicles (UAVs) to Indian potential customers such as Indian Defence Forces, Paramilitary Forces and Central Armed Police Forces at DefExpo 2020.

Hindustan Petroleum Corporation reported 167.80% rise in consolidated net profit to Rs 1,027.23 crore on 1.98% fall in total income to Rs 71,371.09 crore in Q3 December 2019 over Q3 December 2018.

Hero MotoCorp and Eicher Motors will release numbers for the third quarter today, 6 February 2020.

Engineers India reported 19.50% rise in consolidated net profit to Rs 111.82 crore on 51.42% rise in total income to Rs 965.84 crore in Q3 December 2019 over Q3 December 2018.

GE Power India reported 146.06% rise in consolidated net profit to Rs 100.81 crore on 45.69% rise in total income to Rs 841.20 crore in Q3 December 2019 over Q3 December 2018. The company earned exceptional item of Rs 56.53 crore gain on sale of Vadodara factory land & building. The company ended the quarter with an order backlog of Rs 8818 crore.

Lupin announced that it has received approval for its Leflunomide Tablets USP, 10 mg and 20 mg, from the United States Food and Drug Administration (U.S. FDA), to market a generic equivalent of Arava Tablets, 10 mg and 20 mg, of SanofiAventis. The product would be manufactured at Lupin's Pithampur (Unit 1) facility, India. Leflunomide Tablets USP, 10 mg and 20 mg, are indicated for the treatment of adults with active rheumatoid arthritis (RA).

DLF reported 23.53% rise in consolidated net profit to Rs 414.01 crore on 26.67% fall in total income to Rs 1,764.27 crore in Q3 December 2019 over Q3 December 2018. The company declared interim dividend of Rs 1.20 per share.

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Feb 06 2020 | 8:31 AM IST

Next Story